Dynamic Technology Lab Private Ltd Purchases New Position in Inogen, Inc $INGN

Dynamic Technology Lab Private Ltd acquired a new stake in Inogen, Inc (NASDAQ:INGN) in the second quarter, according to its most recent filing with the SEC. The fund acquired 12,755 shares of the medical technology company’s stock, valued at approximately $90,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of INGN. CWM LLC boosted its holdings in shares of Inogen by 11.0% in the second quarter. CWM LLC now owns 16,258 shares of the medical technology company’s stock worth $114,000 after acquiring an additional 1,611 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in Inogen by 1.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 124,993 shares of the medical technology company’s stock worth $891,000 after purchasing an additional 1,751 shares in the last quarter. American Century Companies Inc. lifted its holdings in Inogen by 6.4% during the 1st quarter. American Century Companies Inc. now owns 58,380 shares of the medical technology company’s stock worth $416,000 after purchasing an additional 3,524 shares in the last quarter. Deutsche Bank AG boosted its stake in Inogen by 61.6% in the 1st quarter. Deutsche Bank AG now owns 14,856 shares of the medical technology company’s stock worth $106,000 after purchasing an additional 5,664 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Inogen by 44.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 20,078 shares of the medical technology company’s stock valued at $150,000 after buying an additional 6,220 shares in the last quarter. Institutional investors own 89.94% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Inogen in a report on Monday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Inogen has a consensus rating of “Hold” and a consensus target price of $11.00.

Inogen Stock Performance

NASDAQ:INGN opened at $7.12 on Friday. Inogen, Inc has a 52-week low of $5.70 and a 52-week high of $12.91. The stock has a fifty day moving average of $7.94 and a 200 day moving average of $7.34. The firm has a market capitalization of $193.31 million, a price-to-earnings ratio of -7.05 and a beta of 1.83.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Wednesday, November 5th. The medical technology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.02. The firm had revenue of $92.39 million for the quarter, compared to analysts’ expectations of $92.20 million. Inogen had a negative return on equity of 13.21% and a negative net margin of 7.31%. Inogen has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts forecast that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.